UBS Maintains Buy on Repligen, Raises Price Target to $225
UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.
Stocks · News reference
8-K filing — REPLIGEN CORP (RGEN)
Filed: 2026-09-08 AccNo: 0001193125-26-385380 Size: 151 KB Item 8.01: Other Events
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.
Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $185